Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with active control (moderate certainty).
1 finding from 1 review
Serious adverse events ( · preventing the progression of CKD
Metformin showed no clear difference in serious adverse events ( compared with placebo (moderate certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Immunomodulatory drug maintenance therapy may leads to higher grade 3/4 adverse events compared with placebo/observation (low certainty).
1 finding from 1 review
Grades 3 and 4 adverse events · people with chronic lymphocytic leukaemia
Anti‐CD20 mAb maintenance therapy may leads to higher grade 3/4 adverse events compared with observation (low certainty).
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
1 finding from 1 review
Adverse events at 1 year · bullous pemphigoid
Mild clobetasol propionate cream regimen (10 to 30 g/day) showed no clear difference in adverse events at 1 year compared with standard clobetasol propionate cream regimen (40 g/day) (low certainty).
1 finding from 1 review
Anxiety (adverse effect, post‐intervention) · migrants
1 finding from 1 review
Anxiety (adverse effect, post‐intervention) · migrants
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Sarilumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Clazakizumab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether olokizumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Siltuximab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
Levilimab showed no clear difference in serious adverse events ( compared with standard care/placebo (low certainty).
1 finding from 1 review
Serious adverse events ( · people with mild/moderate/severe/critical COVID‐19
It is very uncertain whether tociliuzumab changes serious adverse events ( compared with standard care/placebo (very low certainty).
1 finding from 1 review
Long‐term adverse events · women with breast cancer and one to three positive lymph nodes
1 finding from 1 review
Adverse events: nausea · adults (aged 18+) with colorectal cancer
It is very uncertain whether adjunctive Coriolus versicolor changes adverse events: Nausea ‐ compared with no adjunctive treatment (very low certainty).
1 finding from 1 review
Serious adverse events ( · hospitalised individuals with unknown vaccination status and a confirmed diagnosis of symptomatic COVID‐19
1 finding from 1 review
Serious adverse events ( · hospitalised and unvaccinated individuals with a confirmed or suspected diagnosis of symptomatic COVID‐19
1 finding from 1 review
Adverse events (6 weeks' · primary Raynaud's phenomenon
Prostagladin/prostacyclin analogues may leads to higher adverse events (6 weeks' compared with placebo (low certainty).
1 finding from 1 review